BergenBio Fundamentale Forhold (BGBIO)

vcp · mars 17, 2022, 7:55am

Kort fortalt; Bra potensiale innenfor et gigantisk marked.

BgBio har allerede fått FDA Fast track her, etter respons i en NSCLC subgruppe.

Subgruppen utgjør ca; 20% av dette markedet:

Konventet den summen til nok

Fornybar · mars 17, 2022, 7:55am

Systemic inhibition of AXL by the BerGenBio molecule bemcentinib led to
increased type I interferon secretion from AXL-expressing dendritic cells,
resulting in expansion of the TCF1+ T cell population and restored therapeutic
response to immune checkpoint blockade treatment. These results were observed in
both an immunocompetent mouse model and in mice bearing human STK11/LKB1 mutant
NSCLC tumors along with a humanized immune system. The paper also summarizes
clinical data in NSCLC patients with identified STK11/LKB1 mutations receiving
bemcentinib and immune checkpoint blockage (pembrolizumab), who demonstrated
objective clinical response to combination therapy.

Når du gir BEM til en pasient øker utskillelse av Type 1 interferon (et stoff som er viktig for at immunforsvaret skal gi respons) fra dendritiske celler som uttrykker AXL. Dendritiske celler er en del av immunforsvaret, og disse ønsker du at skal være parat til å ta opp antigener og å lære opp T-celler til å angripe farlige ting. Det førte til en økning av T-celler og en gjenopprettet terapeutisk respons med sjekkpunkthemmere, dvs at immunforsvaret begynte å fungere igjen da de også gav sjekkpunkthemmere.

Disse forsøkene gjorde de i mus med friskt immunforsvar og i mus innsatt med STK11-mutert NSCLC (lungekreft) og innsatt menneskelig immunceller.

I tillegg har de sett på data fra pasienter i de andre lungekreftstudiene med bekreftet STK11-mutasjon.

BillyP · mars 17, 2022, 9:41am

Så et marked på NOK 70 milliarder på sikt. Hvs målgruppen utgjør 20% av tilfellene. Korrekt?

vcp · mars 17, 2022, 10:17am

Blir vel det, jeg ser det er litt varierende tall.
Om en er litt konservativ kan en si 50 milliarder, årlig

Får de gode nok resultater her, så står nok BP klar med en fin sum.

Men de køddene venter til moden data + så jeg forventer ikke avtale med det første.
Men et studie samarbeid er ikke helt utenkelig. De har en del av dem i pipen allerede.

Når jeg først er inne på det, hvor stor del av pipen er priset inn på det kursnivået en ser nå?
Enten vet noen, noe vi burde vist eller så er det ikke mye som er verdsatt.

Bare at familien Mohn er største eier er verd et par milliarder. Lol😄

Realize_1 · mars 17, 2022, 7:38pm

Tekspert · april 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@vcp (181 likes)

@Matadoren (125 likes)

@Direkte (80 likes)

Resten av topp 10:

@PankPinter (77 likes)
@Hayen (55 likes)
@romaper (47 likes)
@drdr (35 likes)
@Bonus (31 likes)
@OpulentusTT (31 likes)
@Boms (23 likes)

Gratulerer!

TekBot · april 7, 2022, 12:01pm

BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021

Bergen, Norway - 7 April 2022- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announces that the Board of Directors today approved the
…

Vis børsmeldingen

2021 Annual Financial Statements prepared in accordance with International
Financial Reporting Standards (IFRS).

The Annual Report for 2021 and ESEF file are attached to this release and are
also available on BerGenBio ASA’s website
Financial Reports - BerGenBio

Contacts:

For BerGenBio: Martin Olin CEO, BerGenBio ASA

[email protected]

Rune Skeie, CFO, BerGenBio ASA
[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
[email protected]
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to potentially identify patient populations most
likely to benefit from AXL inhibition: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · april 7, 2022, 1:02pm

BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING

Bergen, Norway - 7 April 2022: BerGenBio ASA (OSE:BGBIO) will be holding its
Annual General Meeting virtually on 28 April 2022 at 10:00 hours (CEST).

…

Vis børsmeldingen

The notice, power of attorney and proposal from Nomination Committee are
attached to this release. The notice will be sent to all registered shareholders
and is available on the Company’s website:
General Meetings - BerGenBio

All shareholders are encouraged to exercise their shareholder rights, either
through advance electronically voting through VPS Investor Services, by using
the enclosed proxy form to provide proxy to the Chairman Anders Tullgren (or the
person he appoints), or to attend the general meeting virtually.
Advance vote or proxy for the Annual General Meeting can be registered through
the company’s website or VPS Investor Service within 25 April 2022 16:00 hours
(CEST). Virtual participants need to be logged in to the meeting before 10:00
hours (CEST) 25 April 2022.

All shareholders will receive a reference number and a pin code required for
registration through the company’s website. Reference number and pin code will
be received either by VPS Investor Service or by post depending if the
shareholder is registered as electronical user.
We encourage all shareholders to register as electronical user in VPS.

END -

AboutBerGenBioASA

BerGenBiois a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate,bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broadphase II clinical development programme
focused on combination and single agent therapy in lung cancer, leukaemia and
COVID-19. A first-in-class functional blocking anti-AXL antibody,tilvestamab, is
undergoingphase I clinical testing. In parallel,BerGenBiois developingacompanion
diagnostic test to identify patient populations most likely to benefit
frombemcentinib: this is expected to facilitate more efficient registration
trials supporting a precision medicine-based commercialisation strategy.

BerGenBiois based in Bergen, Norway with a subsidiary in Oxford, UK. The company
is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information,
visit?www.bergenbio.com

Contacts

Martin Olin, CEO, BerGenBio ASA
[email protected]

Rune Skeie, CFO, BerGenBio ASA
[email protected]

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · april 11, 2022, 5:01am

BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer

Bergen, Norway, 11 April 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, today announces the appointment of Cristina Oliva, MD as
…

Vis børsmeldingen

Chief Medical Officer (CMO), effective 25 April 2022. Cristina joins the senior
leadership team heading up clinical development of BerGenBio’s selective AXL
inhibitor programs.

Cristina is a Board-certified oncologist and brings over 20 years of senior
clinical development experience across large pharmaceutical, biotechnology and
Clinical Research Organizations (CROs). Most recently Cristina was Vice
President, Oncology and Head of Oncology Centre of Excellence at IQVIA Ltd,
where she led the development of decentralized trials and established and led
the IQVIA Oncology Global Scientific Advisory Board. Prior to her role at IQVIA,
Cristina held senior positions leading oncology development programs for Nordic
Nanovector, Takeda Pharmaceuticals, GlaxoSmithKline and Eli Lilly.

Martin Olin, Chief Executive Officer of BerGenBio, commented: “I’m delighted to
welcome Cristina as our new Chief Medical Officer. Cristina’s leadership
experience within oncology drug development across big pharma, biotech and CRO
environments will be instrumental in executing BerGenBio’s development strategy
for our AXL inhibitor programs, including our most advanced program bemcentinib,
currently in phase II trials.”

On her appointment as Chief Medical Officer at BerGenBio, Cristina Oliva, MD,
commented:“BerGenBio is on the frontier of developing novel, highly selective
AXL inhibitors for the treatment of severe diseases such as oncology and
respiratory infections. I’m very excited to join BerGenBio at this critical
phase and look forward to working with the senior leadership team to help
further advance its AXL inhibitor programs.”

Contacts:

For BerGenBio: Martin Olin CEO, BerGenBio ASA

[email protected]

Rune Skeie, CFO, BerGenBio ASA
[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
[email protected]
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · april 25, 2022, 5:01am

BERGENBIO PRESENTS BEMCENTINIB COVID-19 CLINICAL TRIAL DATA AT ECCMID 2022

Bergen, Norway, 25 April 2022 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announces that it is presenting data today from its Phase
…

Vis børsmeldingen

IIa bemcentinib COVID-19 clinical trial (BCBC020) in a poster presentation at
the 32nd European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID), being held both online and in-person in Lisbon, Portugal, from April
23-26, 2022.

The poster presentation will share findings from the Company’s Phase IIa open
label study of 115 patients evaluating bemcentinib in combination with Standard
of Care (SoC) compared to a SoC control arm in the treatment of moderate to
severe COVID-19 patients, immediatelyafter hospital admission (BGBC020).

Clinical data from the study show that bemcentinibtreatment (up to 14 days)
confers early and sustained protection, limiting clinical deterioration in
patients. Bemcentinib treated patients were discharged earlier from the
hospital, required less supplementary oxygen and demonstrated a significant
reduction in the need for intubation or ventilation.

Biomarker analysis demonstrates that treatment with bemcentinibreduced markers
of acute inflammation and profibrotic cytokines, and increased expression of
protective factors. These changes were more pronounced in patients with more
serious disease, determined by high C-Reactive Protein (CRP) rates, high
neutrophil to lymphocyte ratio (N/L) ratio or increased oxygen usage.

Preclinical data is also being presented from in vitro studies in lung
epithelial cells on bemcentinib’s activity on variants of concern. These data
suggest that bemcentinib inhibits infection of multiple SARS-CoV-2 variants,
including Omicron, building on previous preclinical research from the Company.

Martin Olin, CEO of BerGenBio, commented: “The data we are presenting at ECCMID
today further demonstrates the effectiveness of bemcentinib as a treatment for
severe respiratory infections such as COVID-19. We have been pleased to see
bemcentinib’s impact on reducing disease deterioration in patients. In addition,
we’re encouraged to see that bemcentinib exerts a broad anti-inflammatory and
pro-repair effect on blood biomarkers. We look forward to the initiation of the
EUSolidAct platform trial which will further assess bemcentinib in hospitalised
COVID-19 patients.”

Details of today’s poster presentation are as follows:

Abstract: 04778: Bemcentinib modulation of inflammatory, fibrotic and tissue
repair pathways correspond with favourable clinical outcomes in hospitalised
COVID-19 patients demonstrating higher severity cues: a biomarker perspective

Session Name: 12c. Clinical features, case management, outcome (incl long-term):
programme no. L0383

Time, Location: Monday, 25th April 2022, 12:00pm - 13:00pm (WEST)

-End-

Contacts:

Martin Olin CEO, BerGenBio ASA

[email protected]

Rune Skeie, CFO, BerGenBio ASA
[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
[email protected]
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · april 26, 2022, 5:00am

BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET

Complete data analysis confirms that the primary endpoint of improved clinical
response and key secondary endpoints were met in a subprotocol under the
platform ACCORD2 study where bemcentinib was added to standard of care therapy
…

Vis børsmeldingen

BerGenBio to confirm the ACCORD2 data by progressing bemcentinib into EU
-SolidAct, a pan-European platform COVID-19 study enrolling up to 500 patients

Bergen, Norway,April 26, 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announced today that a complete data analysis of a
randomized phase II study of bemcentinib in combination with standard of care
(SoC) therapy, ACCORD2 (BGBIL019), in hospitalized COVID-19 patients confirms
that the primary efficacy endpoint was met.

At the July 2021 European Congress of Clinical Microbiology & Infectious
Diseases (ECCMID) meeting, the Company previously presented preliminary data
from the ACCORD2 study in combination with a second COVID-19 study (BGBC020)
showing evidence of therapeutic benefit on meaningful clinical endpoints in a
total of 177 patients. Today’s announcement is the first time complete ACCORD2
data in a total of 61 treated patients has been separately reported.

Overall, 90% of patients treated with bemcentinib + SoC (26 of 29) experienced a
clinical response by day 29 (median 7.0 days), as defined by either a two-point
improvement in World Health Organization (WHO) category from baseline score, or
discharge from hospital, whichever arose sooner. This compared to 69% (22 of 32
patients) with a clinical response to SoC treatment alone (median 9.5 days),
showing statistical significance.

The data was generated under a sub-protocol of the platform ACCORD2 study
(ACCORD2; EudraCT 2020-001736-95 - BGBIL019), a multi-center phase II randomized
study designed to assess the efficacy and safety of candidate agents as add-on
therapies to SoC for the treatment of COVID-19 in hospitalized patients.

Overall, 98% of patients received dexamethasone or an equivalent steroid in
their SoC, and 18% received immunomodulatory treatment with tocilizumab. The
antiviral remdesivir was used in 53% of those randomized to SoC alone, and in
21% of patients treated with bemcentinib.

In addition, key secondary endpoints saw statistically significant improvements
for the bemcentinib + SoC arm compared to SoC alone, including avoidance of any
deterioration by ?1-point increase in WHO score (including death) and ventilator
-free survival over 29 days. At day 29, 97% of bemcentinib + SoC treated
patients were alive compared to 81% of SoC-alone.

Bemcentinib treatment was well tolerated in this patient population, with no
clinically relevant safety signals in comparison to standard of care treatment.

These latest results underline bemcentinib’s potential in COVID-19 and other
severe respiratory infections. As previously announced, bemcentinib will be
studied in the EU-SolidAct trial in up to 500 hospitalized COVID-19 patients.

Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS, Professor of Respiratory
Medicine and Chief Investigator on the ACCORD program commented:“With COVID-19
still driving hospital admissions globally it is key that new, more effective
treatments are being developed. These results from the ACCORD2 program indicate
that bemcentinib has demonstrated real promise as a new therapeutic option for
hospitalized patients and it now warrants testing in larger studies. These
results are a testament to the great collaboration between the NHS, NIHR, the
MEU and our Southampton research teams with more exciting results to follow from
the platform.”

Martin Olin, Chief Executive Officer of BerGenBio, commented:“We are highly
encouraged by the final data from our ACCORD2 study in hospitalized COVID-19
patients. The ability of bemcentinib to add a statistically significant benefit
in clinical response over standard of care therapy is promising. We look forward
to moving to the next step in the development of bemcentinib for COVID-19
through our participation in the EUSolidAct platform study, designed to enrol up
to 500 hospitalized COVID-19 patients.”

Contacts:

For BerGenBio: Martin Olin CEO, BerGenBio ASA

[email protected]

Rune Skeie, CFO, BerGenBio ASA

[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications

[email protected]
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

About ACCORD2 study

Under the bemcentinib sub-protocol of the ACCORD2 study, patients were enrolled
within a calendar day after being admitted to hospital. Eligible patients were
categorized by the WHO 9-point clinical scale and ranged from patients who did
not require supplementary oxygen (grade 3) to those requiring non-invasive
ventilation or high-flow nasal oxygen, but not intubated (grade 5). In the
bemcentinib sub-protocol 29 patients were randomized and received bemcentinib
treatment in addition to SoC.

For further details: A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients - Full Text View - ClinicalTrials.gov

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · april 26, 2022, 8:53am

BERGENBIO TO PRESENT AT ARCTIC SECURITIES BIOTECH WEBINAR

Bergen, Norway, 26 April 2022 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, is pleased to announce that CEO Martin Olin will be
…

Vis børsmeldingen

presenting at the ArcticSecuritiesBiotech Webinar taking place today at 12:55
CET.

The presentation will be made available on the Company’s website in the
Investors section shortly after the presentation.

-Ends-

Contacts

Martin Olin
Chief Executive Officer, BerGenBio ASA
[email protected]

Rune Skeie
Chief FinancialOfficer, BerGenBio ASA
[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

ConsiliumStrategic Communications
[email protected]
+44 20 3709 5700

AboutBerGenBioASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing a
potential companion diagnostic test to identify patient populations most likely
to benefit from AXL inhibition: this is expected to facilitate more efficient
registration trials supporting a precision medicine-based commercialisation
strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit? www.bergenbio.com

Kilde

TekBot · april 28, 2022, 9:28am

BerGenBio ASA: Minutes from the Annual General Meeting

Bergen, Norway, 28 April 2022 - Annual general meeting of BerGenBio ASA was
virtually held today 28 April 2022 at 10.00 CET.

…

Vis børsmeldingen

All proposals were resolved as presented in the notice convening the annual
general meeting distributed on 7 April 2022, as further set out in the minutes
from the annual general meeting attached hereto and available at
General Meetings - BerGenBio.

For further information, please contact:

Martin Olin

CEO, BerGenBio ASA

[email protected]

Rune Skeie

CFO, BerGenBio ASA

[email protected]

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Tekspert · mai 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@PankPinter (157 likes)

@vcp (148 likes)

@Matadoren (138 likes)

Resten av topp 10:

@Direkte (86 likes)
@Hayen (55 likes)
@romaper (46 likes)
@drdr (44 likes)
@Bonus (31 likes)
@OpulentusTT (27 likes)
@Boms (26 likes)

Gratulerer!

TekBot · mai 4, 2022, 5:01am

BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19

· BerGenBio to focus on two key opportunities for its lead compound bemcentinib
· Strategic focus anchored in strong scientific rationale, supported by
dataset from over 600 patients demonstrating bemcentinib’s biological and
…

Vis børsmeldingen

clinical activity matched with significant unmet medical needs

Bergen, Norway,4 May 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announces today an update on its business strategy.
BerGenBio will now focus on two key indications; 1st line non-small cell lung
cancer (NSCLC) and COVID-19, which the Company believes offer the optimal path
towards translating BerGenBio’s strong scientific foundation into significant
value generation from marketed products to address unmet medical needs.

The opportunity

BerGenBio has for many years pioneered research into AXL inhibition, with its
lead development candidate bemcentinib showing clinical potential in oncology
and infectious disease. With over 600 patients dosed (approx. 400 in oncology
and approx. 200 in COVID-19), the Company has built a large dataset
demonstrating biological and clinical activity while simultaneously defining
dosing regimens to identify an appropriate balance of safety and efficacy.

The updated business strategy announced today builds on bemcentinib’s mode of
action and data gathered from a broad clinical exploration to progress two
distinct opportunities with the potential to significantly improve the lives of
patients: NSCLC and COVID-19. Both indications show strong evidence of
bemcentinib activity, with the advantage of accumulation in target organs,
options for accelerated registration, compelling competitive advantages, and
both represent high unmet medical needs.

Martin Olin, Chief Executive Officer of BerGenBio, commented:"BerGenBio has been
at the forefront of understanding of AXL biology and, having pioneered this
area, we remain confident that selective AXL inhibition holds significant
potential as a transformative treatment modality for several serious diseases. A
rapidly evolving treatment landscape, with improved standards of care in areas
such as oncology requires BerGenBio to be nimble and identify specific
opportunities where we can address unmet needs in a competitive manner.

With this in mind we believe that by introducing a laser focus and rightsizing
the organization on two key areas where we see our pipeline has the greatest
impact, we are efficiently advancing BerGenBio’s potential; building on our
strong scientific foundation to deliver new drugs to market resulting in better
outcomes for patients and the generation of significant value for our
shareholders."

NSCLC

Despite advances in treatment, lung cancer remains the leading cause of cancer
-related deaths throughout the world.Approximately 85% of lung cancers are
classified as NSCLC. BerGenBio is targeting 1st Line STK11 mutated Non-Squamous
NSCLC patients, an extremely large patient population with very limited response
to the standard of care treatments. STK11 is an important tumor suppressor gene
reported to confer immunotherapy resistance in NSCLC and is present in up to 20%
of NSCLC patients.

Pre-clinical and clinical studies have suggested a mechanism by which
bemcentinib may restore response to immune checkpoint inhibitor therapy and
enable the avoidance of chemoresistance in NSCLC patients harboring STK11
mutations, thus potentially offering a treatment option to those patients who
respond poorly to existing therapies. Data from the subset of STK11mutated
patients treated in the Company’s BGB008 study in 2nd line NSCLC also provides
early indications of efficacy in this biomarker driven patient population.

The FDA has recognized that STK11 is currently a “non-actionable” mutation - one
that confers poor outcome and has no specific therapeutic approaches today and
have granted BerGenBio a Fast Track Designation for bemcentinib in this setting.
To date, bemcentinib is to the Company’s knowledge the only selective AXL
inhibitor in development for patients with STK11 mutation. BerGenBio has a
strong proprietary position for treatment of this population and believes there
may be a potential for an accelerated approval pathway in this patient sub-set.

COVID-19

Despite the success of vaccines, there is still a large number of hospitalized
patients that remain in need of improved therapeutic options for COVID-19.
Research into bemcentinib’s potential in hospitalized COVID-19 patients began in
2020, in response to the emergence of the pandemic, and based on the Company’s
understanding of AXL’s role in mediating aggressive diseases.

Recently, BerGenBio announced results from the Phase II sub-protocol of the
platform ACCORD2 study, which met its primary and key secondary endpoints, with
demonstrable efficacy in patients on top of current standard-of-care treatments
including remdesivir and corticosteroids. Further, bemcentinib has been selected
to be studied under the EUSolidAct platform trial through a sub-protocol
enrolling 500 patients across European sites. Given the ongoing need for new
treatment options for hospitalized COVID-19 patients, the novel mechanism of
action of bemcentinib (independent of the spike protein), along with potential
to confirm the ACCORD2 data in theEUSolidAct trial,the Company believes that
this could warrant Emergency Use Authorizations based on precedents.

The Company believes that the unique mechanism of action and properties of
bemcentinib positions it well as a novel treatment modality within severe
respiratory infections beyond COVID-19.

With a focused strategy and rightsized organization BerGenBio plans to unlock
significant potential value related to the two indications selected and define
the path to market.

An investor call will take place today at 1pm CEST (7am ET), full details below.

Web link: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20220504_12

Dial-in details:

PIN Code: 712491

NO: +47-21-956342

UK: +44-203-7696819

US: +1 646-787-0157

SE: +46-4-0682-0620

DK: +45 78768490

Contacts:

For BerGenBio:

Martin Olin CEO, BerGenBio ASA

[email protected]

Rune Skeie, CFO, BerGenBio ASA

[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications

[email protected]
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · mai 16, 2022, 5:00am

BERGENBIO TO PRESENT AT ABG SUNDAL COLLIER LIFE SCIENCE SUMMIT

Bergen, Norway, 16 May 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, is pleased to announce that CEO Martin Olin will be
…

Vis børsmeldingen

presenting at the ABG Sundal Collier Life Science Summit taking place on
Wednesday 18 May at 11:30 CEST.

The presentation slides will be made available on the Company’s website in the
Investors section shortly after the presentation.

-Ends-

Contacts

Martin Olin CEO, BerGenBio ASA

[email protected]

Rune Skeie, CFO, BerGenBio ASA
[email protected]
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
[email protected]
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Kilde

TekBot · mai 18, 2022, 5:02am

BERGENBIO ASA: INVITATION TO FIRST QUARTER 2022 RESULTS WEBCAST

Bergen, Norway, 18 May 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, will be announcing its results for the first quarter 2022
…

Vis børsmeldingen

on Tuesday 24 May 2022.

A presentation and live webcast by BerGenBio’s senior management team will take
place at 10:00 am CET, followed by a Q&A session.

The live webcast link will be available at www.bergenbio.com in the
Investors/Financial Reports section and a recording will be available shortly
after the webcast has finished.

The first quarter report and presentation will be made available on the
Company’s website in the Investors/Financial Reports section from 7:00am CET the
same day.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

[email protected]

Rune Skeie, CFO, BerGenBio ASA
[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
[email protected]
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · mai 24, 2022, 5:01am

BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2022

Bergen, Norway, 24 May 2022 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, announces its results for the first quarter 2022.
…

Vis børsmeldingen

A briefing by BerGenBio’s senior management team will take place at 10:00am CEST
today via a webcast presentation, followed by a Q&A session. Please see below
for details.

Operational Highlights - first quarter 2022 (including post-period end)

· Post-period end, business strategy update announced, focusing on two key
indications; 1st line STK11m non-small cell lung cancer (NSCLC) and COVID-19.
· Primary endpoint met in hospitalized COVID-19 patients in complete data
analysis of ACCORD2 (BGBIL019), a randomized Phase II study of bemcentinib in
combination with standard of care therapy.
· Presented clinical trial data from Phase IIa bemcentinib COVID-19 clinical
trial (BCBC020) at 32nd European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID).
· Cristina Oliva, MD appointed as Chief Medical Officer, bringing over 20
years of senior clinical development experience across large pharmaceutical,
biotechnology and Clinical Research Organizations.
· Publication of a peer-reviewed article entitled “AXL targeting restores PD-1
blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8+
T cells” in the journal Cell Reports Medicine.

· Announced inclusion ofbemcentinib, in the EUSolidAct platform study of
hospitalized COVID-19 patients designed to enroll up to 500 patients across
European centers participating in the EUSolidAct platform.

Financial Highlights - first quarter 2022

(Figures in brackets = same period 2021 unless otherwise stated)

· Revenue amounted toNOK 0.0 million (NOK 0.0 million) for the first quarter
2022
· Total operating expenses for the first quarter were NOK 78.6 million (NOK
83.4 million)
· The operating loss for the first quarter came toNOK78.6 million
(NOK83.4million)
· Cash and cash equivalents amounted to NOK 367.8 million at the end of the
first quarter 2022 (NOK 436.6 million by end of December 2021)

Martin Olin, Chief Executive Officer of BerGenBio, commented: "Earlier this
month, we provided an update on the Company’s strategy. BerGenBio’s mission
remains unchanged, and we believe that the announced focus provides an optimal
path to unlock the potential of AXL inhibition as a transformative treatment
modality for severe diseases.

By focusing the development of our lead asset bemcentinib to two key areas,
STK11 mutated (STK11m) 1st line non-small cell lung cancer (NSCLC) and COVID-19,
we believe we have defined the path to efficiently advance BerGenBio’s clinical
and commercial potential. Both indications represent significant unmet medical
needs and our defined plans for each of these indications provides a strong
foundation for bringing new drug to market with the aim of achieving better
outcomes for patients and the generation of significant value for our
shareholders.

With a focused strategy and rightsized organization, I believe we are well
positioned to unlock significant potential value related to the two indications
selected and define the path to market."

Presentation and Webcast Details

The live webcast link is available at www.bergenbio.com in the
Investors/Financial Reports section. A recording will be available shortly after
the webcast has finished.

Webcast link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20220524_3

Dial-in numbers:

NO: +47-21-956342

UK: +44-203-7696819

US: +1 646-787-0157

SE: +46-4-0682-0620

DK: +45 78768490

Pin: 712491

The first quarter report and presentation are available on the Company’s website
in the Investors/Financial Reports section and a recording of the webcast will
be made available shortly after the webcast has finished.

-Ends-

Contacts

Martin Olin
Chief Executive Officer, BerGenBio ASA
[email protected]

Rune Skeie
Chief FinancialOfficer, BerGenBio ASA
[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

ConsiliumStrategic Communications
[email protected]
+44 20 3709 5700

AboutBerGenBioASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies, and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

Kilde

Tekspert · juni 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@vcp (166 likes)

@PankPinter (156 likes)

@Matadoren (153 likes)

Resten av topp 10:

@romaper (69 likes)
@Hayen (63 likes)
@Direkte (54 likes)
@drdr (37 likes)
@Boms (23 likes)
@Bonus (21 likes)
@Roc (21 likes)

Gratulerer!

TekBot · juni 6, 2022, 4:20pm

BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC AT ASCO ANNUAL MEETING 2022

Bergen, Norway, 6 June 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, is pleased to announce presentation of a poster at the ASCO
…

Vis børsmeldingen

Annual Meeting to be held from 3rd - 8th June 2022.

The poster presentation provides clinical data from a Phase 1 dose escalation
and expansion study of bemcentinib (BGB324) in combination with docetaxel in
patients with previously treated advanced non-small cell lung cancer (NSCLC).
The data presented indicate that bemcentinib in combination with docetaxel shows
evidence of anti-tumor activity, with 35% of patients achieving a partial
response and 47% attaining stable disease, and a manageable safety profile in
previously treated, advanced NSCLC.

Cristina Oliva, Chief Medical Officer at BerGenBio, commented: “While the data
are limited, they suggest a mechanism by which treatment with bemcentinib could
delay resistance to and potentiate the effects of chemotherapy treatment in
NSCLC patients.”

The full abstract is available on the ASCO website here:
https://meetings.asco.org/abstracts-presentations/212839

Full details of the presentation are below:

Title:Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a
first-in-class, selective AXL inhibitor, with docetaxel in patients with
previously treated advanced NSCLC.

Author:Bhalla et al.

Session/Abstract ID:Lung Cancer - Non Small Cell Metastatic / 9081

Location/Time: June 6, 2022, Hall D1, 1:25pm Central Time

Contacts:

Martin Olin CEO, BerGenBio ASA

[email protected]

Rune Skeie, CFO, BerGenBio ASA

[email protected]

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications

[email protected]
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on
developing transformative drugs targeting AXL as a potential cornerstone of
therapy for aggressive diseases, including cancer and severe respiratory
infections. The Company is focused on its proprietary lead candidate bemcentinib
a potentiallyfirst-in-class selective AXL inhibitor in development for STK11
mutated NSCLC and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde